Abstract
Spinal cord injury (SCI) leads to profound haemodynamic changes. Constant outflows from the central autonomic pattern generators modulate the activity of the spinal sympathetic neurons. Sudden loss of communication between these centers and the sympathetic neurons in the intermediolateral thoracic and lumbar spinal cord leads to spinal shock. After high SCI, experimental data demonstrated a brief hypertensive peak followed by bradycardia with escape arrhythmias and marked hypotension. Total peripheral resistance and cardiac output decrease, while central venous pressure remains unchanged. The initial hypertensive peak is thought to result from direct sympathetic stimulation during SCI and its presence is anaesthetic agent dependent. Hypotension improves within days in most animal species because of reasons not totally understood, which may include synaptic reorganization or hyper responsiveness of α receptors. No convincing data has demonstrated that the deafferented spinal cord can generate significant basal sympathetic activity. However, with the spinal shock resolution, the deafferented spinal cord (in lesions above T6) will generate lifethreatening hypertensive bouts with compensatory bradycardia, known as autonomic hyperreflexia (AH) after stimuli such as pain or bladder / colonic distension. AH results from the lack of supraspinal control of the sympathetic neurons and altered neurotransmission (e.g. glutamatergic) within the spinal cord. Despite significant progress in recent years, further research is necessary to fully understand the spectrum of haemodynamic changes after SCI.
Keywords: autonomic hyperreflexia, autonomic nervous system, blood pressure, heart rate, spinal cord injury
Current Vascular Pharmacology
Title: Cardiovascular Control After Spinal Cord Injury
Volume: 2 Issue: 1
Author(s): F. A.A. Gondim, A. C.A. Lopes Jr., G. R. Oliveira, C. L. Rodrigues, P. R.L. Leal, A. A. Santos and F. H. Rola
Affiliation:
Keywords: autonomic hyperreflexia, autonomic nervous system, blood pressure, heart rate, spinal cord injury
Abstract: Spinal cord injury (SCI) leads to profound haemodynamic changes. Constant outflows from the central autonomic pattern generators modulate the activity of the spinal sympathetic neurons. Sudden loss of communication between these centers and the sympathetic neurons in the intermediolateral thoracic and lumbar spinal cord leads to spinal shock. After high SCI, experimental data demonstrated a brief hypertensive peak followed by bradycardia with escape arrhythmias and marked hypotension. Total peripheral resistance and cardiac output decrease, while central venous pressure remains unchanged. The initial hypertensive peak is thought to result from direct sympathetic stimulation during SCI and its presence is anaesthetic agent dependent. Hypotension improves within days in most animal species because of reasons not totally understood, which may include synaptic reorganization or hyper responsiveness of α receptors. No convincing data has demonstrated that the deafferented spinal cord can generate significant basal sympathetic activity. However, with the spinal shock resolution, the deafferented spinal cord (in lesions above T6) will generate lifethreatening hypertensive bouts with compensatory bradycardia, known as autonomic hyperreflexia (AH) after stimuli such as pain or bladder / colonic distension. AH results from the lack of supraspinal control of the sympathetic neurons and altered neurotransmission (e.g. glutamatergic) within the spinal cord. Despite significant progress in recent years, further research is necessary to fully understand the spectrum of haemodynamic changes after SCI.
Export Options
About this article
Cite this article as:
Gondim A.A. F., Lopes Jr. C.A. A., Oliveira R. G., Rodrigues L. C., Leal R.L. P., Santos A. A. and Rola H. F., Cardiovascular Control After Spinal Cord Injury, Current Vascular Pharmacology 2004; 2 (1) . https://dx.doi.org/10.2174/1570161043476474
DOI https://dx.doi.org/10.2174/1570161043476474 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy
Current Pharmaceutical Design Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19
Current Cardiology Reviews Pharmacokinetics of Drugs in Neonates: Pattern Recognition Beyond Compound Specific Observations
Current Pharmaceutical Design Development of Poly(lactide-co-glicolide) Nanoparticles Incorporating Morphine Hydrochloride to Prolong its Circulation in Blood
Current Pharmaceutical Design Ranolazine, a Partial Fatty Acid Oxidation Inhibitor, its Potential Benefit in Angina and Other Cardiovascular Disorders
Recent Patents on Cardiovascular Drug Discovery The Effects of Drugs Used in Anaesthesia on Platelet Membrane Receptors and on Platelet Function
Medicinal Chemistry Reviews - Online (Discontinued) Antinociceptive Effects of Aza-Bicyclic Isoxazoline-Acylhydrazone Derivatives in Different Models of Nociception in Mice
Current Topics in Medicinal Chemistry Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design CRF Receptor Antagonists: Utility in Research and Clinical Practice
Current Medicinal Chemistry Discovery and ADMET: Where Are We Now
Current Topics in Medicinal Chemistry Comparison Between the Effects of Bupivacaine and Levobupivacaine for Spinal Anesthesia on QT Dispersion
Cardiovascular & Hematological Disorders-Drug Targets Capsaicin Sensitive-Sensory Nerves and Blood Pressure Regulation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Hydrogen Sulfide: From Physiology to Pharmacology
Inflammation & Allergy - Drug Targets (Discontinued) Phytochemical and Pharmacological Activity Profile of Crataegus oxyacantha L. (Hawthorn) - A Cardiotonic Herb
Current Medicinal Chemistry Significance of 1,3,4-Oxadiazole Containing Compounds in New Drug Development
Current Drug Research Reviews Oligonucleotide-based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs
Current Drug Targets The Significance of Endothelium-Derived Hyperpolarizing Factor in the Human Circulation
Current Vascular Pharmacology Compendious Review on Bioactive Constituents and Pharmacotherapeutic Profile of Heliotropium indicum Linn
The Natural Products Journal New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design